Hanmi Pharmaceutical announced on January 11 that it would commission production of the plasmid DNA COVID-19 vaccine ZyCoV-D developed by Zydus Cadila of India. It will be produced in earnest from the second quarter of this year at Hanmi Bio Plant, with an annual capacity of 80 million doses.
At the end of last year, Hanmi Pharm and Enzychem Life Sciences, which signed a technology transfer contract with Zydus, started technology transfer and optimization of production facilities for consignment manufacturing of the ZyCoV-D vaccine.
Hanmi Pharm performs process reproduction, production facility optimization, and test method technology transfer to prepare for mass production of DNA vaccines at the Pyeongtaek Bio Plant.
The ZyCoV-D vaccine is a COVID-19 genetic vaccine that was approved for emergency use by Drugs Controller General of India (DCGI) in August last year.
It is not sensitive to temperature, so it is stored at 2~8℃ and can be stored for 3 months even at 25℃, which is advantageous for global supply.
